FAILED TRIAL: Ph 2/3 SKYSCRAPER-06 trial of tiragolumab, Tecentriq and chemo did not meet the primary endpoints of PFS at primary analysis and OS at first interim analysis July 9, 2024
RYBREVANT (amivantamab) + chemo approved in the EU for 1L treatment of patients with advanced NSCLC with activating EGFR ex 20 insertion mutations July 9, 2024
Focus on vebreltinib study enrollment for NSCLC patients with Met Amplification mutations announced July 9, 2024
Tagrisso + chemo approved in the EU as new 1L treatment for patients with EGFR-mutated advanced lung cancer July 9, 2024
Tagrisso + chemo approved in China & Japan as 1st-line treatment for patients with EGFR-mutated advanced lung cancer July 1, 2024
Patritumab Deruxtecan BLA Submission Receives CRL from FDA Due to Inspection Findings at Third-Party Manufacturer July 1, 2024
FAILED TRIAL: ADJUVANT BR.31 Ph 3 trial of Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of DFS vs placebo in early-stage (IB-IIIA) NSCLC July 1, 2024
FDA grants Fast Track Designation for ABD-147 for the Treatment of Patients with Extensive-stage SCLC July 1, 2024
GALAXIES Lung-301 Ph 3 study of Belrestotug and Dostarlimab in 1L Unresectable Locally Advanced/Metastatic PD-L1 Selected NSCLC initiated June 25, 2024
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors June 18, 2024
Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer June 18, 2024
European Commission approves Alecensa as the adjuvant treatment for people with ALK-positive early-stage lung cancer June 18, 2024
Tagrisso with the addition of chemo recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer June 11, 2024
IND Filing for PFL-002/VERT-002 for Patients with Solid Tumors Including NSCLC with MET Alterations June 11, 2024
FDA grants Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR WT NSCLC June 4, 2024
FAILED TRIAL: Datopotamab deruxtecan showed clinically meaningful OS improvement vs. chemo in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial May 29, 2024
NMPA of China Accepted and Granted Priority Review Designation to the NDA for Glecirasib May 29, 2024
US FDA accepts Protocol for New Randomized Ph 2 Study of NBTXR3 for Patients with Stage 3 Lung Cancer May 21, 2024
